Evaluating a new combination therapy for high blood pressure

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the safety and efficacy of a fixed-dose combination therapy (SPC1001) consisting of candesartan, amlodipine, and indapamide in adults with essential hypertension. Participants will be randomly assigned to receive either the triple combination therapy or dual-component therapies for a duration of 8 weeks. The study will involve multiple centers and will utilize a double-blind, parallel-group design to ensure unbiased results. Screening will occur within four weeks prior to randomization to confirm eligibility based on blood pressure measurements.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Men and women aged 19 to 75 years whose blood pressure measured at the screening visit meets the following criteria.

Exclusion Criteria:

* Patients whose blood pressure measured at the screening and randomization visits meets the criteria of MSSBP ≥180 mmHg or MSDBP ≥110 mmHg, among other conditions.

Where it's running

• CHA Gangnam Medical Center, CHA University, Seoul, Republic of Korea
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: YeongJin Jeong, Master
• Email: yjjeong@shinpoong.co.kr
• Phone: +82 2-2189-3944

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Abnormal menstrual bleeding in women on antithrombotic drugs after heart surgery

  This study looks at whether women on blood thinners after heart surgery have abnormal menstrual bleeding and what factors might put some at higher risk.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07870941

• AI-powered ECG to help diagnose and predict outcomes in heart disease

  Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.

  Recruiting Inha University Hospital · Incheon, Incheon · NCT07856472

• Colchicine for preventing cardiovascular disease in adults with type 2 diabetes

  A 24-week study will test whether low-dose colchicine can help protect blood vessels in adults with type 2 diabetes who have not yet developed artery disease, compared with a placebo.

  Recruiting Phase 2 Tan Tock Seng Hospital · Singapore, Singapore · NCT07837934

• Optimised Cardio-Renal Care for CKD and heart disease

  This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.

  Recruiting Odense University Hospital · Svendborg · NCT07835828

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

• One-stop photon-counting CT for patients after PCI

  This study tests a single CT exam using photon-counting technology to image the heart after stent placement in people who have had PCI.

  Recruiting Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07763340

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.